Kaligia Bioscience has begun clinical tests with it’s Rapid Biofluid Analyzer utilizing saliva to detect COVID-19 in just three minutes.
The technology was originally developed to find a less invasive way for people with diabetes to test their glucose levels. With the onset of the virus, Kaligia has adopted the methodology and machine learning to provide a more effective option to quickly test patients. Clinical trials have begun this week with local healthcare providers.
Unlike other tests which analyze samples with six-inch nasal swabs, Kaligia’s Rapid Biofluid Analyzer 2 points a laser at the collected saliva sample to reveal the underlying chemical components and then draws on machine learning to identify positive and negative results.